Lisata Therapeutics Stock Investor Sentiment

LSTA Stock  USD 2.65  0.04  1.53%   
About 51% of Lisata Therapeutics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Lisata Therapeutics suggests that some traders are interested. The current market sentiment, together with Lisata Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Lisata Therapeutics stock news signals to limit their universe of possible portfolio assets.
  

Lisata Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Lisata Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over two months ago at globenewswire.com         
Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab
Macroaxis News: globenewswire.com
over two months ago at investing.com         
Avidity Biosciences executive sells over 578k in stock
Investing News at Macroaxis
over two months ago at benzinga.com         
Goldman Sachs Bullish On Avidity Biosciences, Cites Scalable RNA Therapeutics Platform For Rare Dise...
benzinga news
over two months ago at finance.yahoo.com         
LSTA Issues Representative Best-Practice LMT Protections for Credit Agreements in Private Corporate ...
Yahoo News
over two months ago at thelincolnianonline.com         
StockNews.com Initiates Coverage on Calithera Biosciences
news
over two months ago at investing.com         
Avidity Biosciences CFO sells over 500k in company stock
Investing News at Macroaxis
over two months ago at prnewswire.com         
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635
prnewswire News
over two months ago at finance.yahoo.com         
Assembly Biosciences Investigational Herpes Treatment Shows Antiviral Efficacy, Safety In Healthy Pa...
Yahoo News
over two months ago at seekingalpha.com         
IDEAYA Biosciences up on positive interim data for its uveal melanoma treatment
seekingalpha News
over two months ago at insidermonkey.com         
Harmony Biosciences Holdings, Inc. Short Seller Sentiment is Bearish
insidermonkey News
over two months ago at accesswire.com         
Stockholders Are Urged To Help The Schall Law Firm Investigate Spruce Biosciences, Inc. For Possible...
news
over two months ago at businesswire.com         
Aditxts Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endo...
businesswire News
over two months ago at finance.yahoo.com         
Precede Biosciences Presents Data on Liquid Biopsy Comprehensive Epigenomic Profiling of MS Patients...
Yahoo News
over two months ago at bizjournals.com         
Parse Biosciences scores victory in patent dispute
bizjournals News
over three months ago at insidermonkey.com         
Hedge Fund and Insider Trading News John Paulson, Steve Cohen, Ray Dalio, Warren Buffett, Dmitry Bal...
insidermonkey News
Far too much social signal, news, headlines, and media speculation about Lisata Therapeutics that are available to investors today. That information is available publicly through Lisata media outlets and privately through word of mouth or via Lisata internal channels. However, regardless of the origin, that massive amount of Lisata data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Lisata Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Lisata Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Lisata Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Lisata Therapeutics alpha.

Lisata Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Forte Biosciences, Inc. Announces Oversubscribed 53 Million Private Placement From Leading ...
11/20/2024
2
Castle Biosciences director Daniel Bradbury sells 243,692 in stock
12/05/2024
3
Castle Biosciences CEO Derek Maetzold sells 160,741 in shares
12/09/2024
4
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring
12/10/2024
5
Lisata Therapeutics Given Buy Rating at HC Wainwright
12/11/2024
6
Parse Biosciences bringt Evercode Mouse BCR auf den Markt, um die Entwicklung und Herstellung von Antikrpern fr Anwendungen in der Arzneimittelforschung zu unte...
12/12/2024
7
Solid Biosciences SWOT analysis gene therapy stocks potential in DMD treatment
12/13/2024
8
Why Forte Biosciences Stock Is Trading Lower
12/16/2024

Complementary Tools for Lisata Stock analysis

When running Lisata Therapeutics' price analysis, check to measure Lisata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lisata Therapeutics is operating at the current time. Most of Lisata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lisata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lisata Therapeutics' price. Additionally, you may evaluate how the addition of Lisata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device